Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.